본문 바로가기

Efficacy and safety of a new 10% intravenous immunoglobulin product in patients with primary immune thrombocytopenia (ITP)

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q2Scopus Q1
피인용
Web of Science 10Scopus 12KCI 0
FWCI (Scopus)
0.47
JCR IF
JCR 2017 1.588
ISSN
1011-8934

저자

  1. Hong, Junshik제1저자Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
  2. Bang, Soo-MeeDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea
  3. Mun, Yeung-ChulDepartment of Internal Medicine, Ewha Womans University Medical Center, Ewha Womans University School of Medicine, Seoul, South Korea
  4. Yhim, Ho-YoungDepartment of Internal Medicine, Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, South Korea
  5. Lee, JaehoonGreen Cross Corp, Yongin, South Korea
  6. Lim, Hyeong-SeokDepartment of Clinical Pharmacology and Therapeutics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
  7. Oh, Doyeun교신저자Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea
  8. Cho, YoonyoungDepartment of Internal Medicine, Catholic University of Daegu School of Medicine, South Korea
  9. Jung, Chul WonDepartment of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea
  10. Nam, Seung-HyunDepartment of Internal Medicine, Seoul Veterans Hospital, South Korea
  11. Song, IkchanDepartment of Medicine, Chungnam National University Hospital, South Korea
  12. Kim, Hyeoung JoonDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, South Korea
  13. Lee, Je-HwanDepartment of Hematology, University of Ulsan College of Medicine, Asan Medical Center, South Korea
  14. 신호진Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, South Korea
  15. Yi, Hyeon GyuDepartment of Hematology-Oncology, Inha University Hospital and School of Medicine, South Korea
  16. Kim, Kyoung HaDepartment of Internal Medicine, Soonchunhyang University College of Medicine, South Korea
  17. Kim, HawkDivision of Hematology and Cellular Therapy, Ulsan University Hospital, University of Ulsan College of Medicine, South Korea
  18. Sohn, Sang KyunDepartment of Hematology/Oncology, Kyungpook National University Hospital, South Korea
  19. Park, Moo-RimDepartment of Internal Medicine, School of Medicine, Wonkwang University, South Korea
  20. Joo, Young-DonDepartment of Internal Medicine, Inje University College of Medicine, South Korea
  21. Lee, Hong GhiDepartment of Internal Medicine, Kunkuk University Medical Center, South Korea

초록

Background: In the current study, we aimed to investigate the efficacy and safety of intravenous immunoglobulin (IVIg)-SN 10%, a new 10% IVIg formulation, in adult patients with severe primary immune thrombocytopenia (ITP; platelet count < 20 × 109/L). Methods: Patients diagnosed as primary ITP, aged 19 years old or more, and had a platelet count of < 20 × 109/L by screening complete blood cell count performed within 2 weeks of study commencement were eligible. Patients received IVIg-SN 10% at a dose of 1 g/kg/day for two consecutive days. Response was defined as the achievement of a platelet count of ≥ 50 × 109/L at day 8. Results: Out of 81 eligible patients, 31 patients were newly diagnosed, 7 patients had persistent ITP, and 43 patients had chronic ITP. In intent-to-treat analysis, 61.3 patients (75.7%) achieved response and satisfied the pre-defined non-inferiority condition. Median time to response was 2 days and mean duration of maintaining response after the completion of IVIg therapy was 9.13 ± 8.40 days. Response rates were not found to be dependent on the phase of ITP or previous treatment for ITP. The drug was well tolerated and the frequency of mucocutaneous bleeding decreased during the study period. Conclusion: In summary, IVIg-SN 10% formulation was found to be safe and effective in adult ITP patients (Trial registry at ClinicalTrials.gov, NCT02063789).

키워드

BleedingHemorrhageImmune thrombocytopeniaIV immunoglobulinsThrombocytopenia

식별자

Scopus EID
2-s2.0-85046657462
WoS UID
000432467400003
KCI
ART002345034